Co-Diagnostics earnings release, May 14, 2026
Exhibit
99.1
Co-Diagnostics
Reports First Quarter 2026 Financial Results
Advancing
Global Commercialization Through CoSara Regulatory Progress and Regional Expansion
Executing
Clinical Strategy with Upper Respiratory Submission Preparation and TB Study Initiation
Expanding
International Presence and Reinforcing Platform Differentiation Through Partnerships and IP
Salt
Lake City, UT – May 14, 2026 – Co-Diagnostics, Inc. (Nasdaq: CODX) (“Co-Dx,” or “the Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the first quarter ended March 31, 2026.
First
Quarter 2026 Business Highlights:
First
Quarter 2026 Financial Results:
“The progress we’ve made across the business is translating into tangible milestones and expanded opportunities,” said Dwight
Egan, Chief Executive Officer of Co-Diagnostics. “During the quarter, we advanced key initiatives across our clinical pipeline, strengthened our presence in strategic global markets through CoSara and CoMira, and continued to build the foundation for a scalable, globally deployable diagnostics platform. These efforts reflect a focused strategy centered on execution, innovation, and expanding our reach into high-need markets.”
Mr.
Egan continued, “We believe we have generated the data needed to support a regulatory submission for our upper respiratory multiplex test and are advancing toward a
510(k) filing with the
FDA.
We are also preparing to initiate clinical performance studies for our
MTB program in India, which we believe represents one of the most significant near-term opportunities for the platform. Together with continued progress across our international initiatives, these developments demonstrate continued operational progress against our strategy and that we are entering the next phase of execution with increasing momentum and a clearer path toward commercialization.”
Recent
Developments:
Conference
Call and Webcast:
Co-Diagnostics will host a conference call and webcast at 4:30 p.m. EDT today to discuss its financial results with analysts and institutional investors.
The conference call and webcast will be available via:
Webcast: ir.co-dx.com on the
Events & Webcasts page, or accessible directly here
Conference
Call: 1-888-880-3330 (Toll Free) or 1-646-357-8766 (Toll)
The call will be recorded and later made available on the Company’s website.
*The
Co-Dx PCR platform (including the PCR
Home
TM, PCR
Pro
TM, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.
About
Co-Diagnostics, Inc.
Co-Diagnostics,
Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies.
The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules
(DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform
(subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.
Non-GAAP
Financial Measures:
This press release contains adjusted EBITDA, which is a non-GAAP measure defined as net income excluding depreciation, amortization, income tax (benefit) expense, net interest (income) expense, stock-based compensation, change in fair value of contingent consideration, and realized gain (loss) on investments. The Company believes that adjusted EBITDA provides useful information to management and investors relating to its results of operations. The Company’s management uses this non-GAAP measure to compare the Company’s performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The Company believes that the use of adjusted EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company’s financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making.
Management does not consider the non-GAAP measure in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of the non-GAAP financial measure is that it excludes significant expenses that are required by GAAP to be recorded in the Company’s financial statements. In order to compensate for these limitations, management presents the non-GAAP financial measure together with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation table of the net income, the most comparable
GAAP financial measure to adjusted EBITDA, is included at the end of this release. The Company urges investors to review the reconciliation and not to rely on any single financial measure to evaluate the company’s business.
Forward-Looking
Statements:
Financial statements
Income Statement
Three Months Ended March 31, — (Unaudited)
| Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 | ||
|---|---|---|---|
| Product revenue | 145,954 | 50,277 | |
| Total revenue | 145,954 | 50,277 | |
| Cost of revenue | 193,768 | 21,590 | |
| Gross profit (loss) | -47,814 | 28,687 | |
| Operating expenses | Sales and marketing | 467,955 | 657,030 |
| Operating expenses | General and administrative | 2,503,126 | 2,773,149 |
| Operating expenses | Research and development | 5,934,071 | 4,870,019 |
| Operating expenses | Depreciation and amortization | 255,445 | 280,445 |
| Operating expenses | Total operating expenses | 9,160,597 | 8,580,643 |
| Operating expenses | Loss from operations | -9,208,411 | -8,551,956 |
| Other income, net | Interest income, net | 6,974 | 13,601 |
| Other income, net | Realized gain on investments | 301,465 | |
| Other income, net | Gain on remeasurement of acquisition contingencies | 75,280 | 717,067 |
| Other income, net | Loss on equity method investment in joint ventures | -13,361 | -1,444 |
| Other income, net | Total other income, net | 68,893 | 1,030,689 |
| Other income, net | Loss before income taxes | -9,139,518 | -7,521,267 |
| Other income, net | Income tax provision | 520 | 12,004 |
| Other income, net | Net loss | -9,140,038 | -7,533,271 |
| Other comprehensive income (loss) | Change in net unrealized gains (losses) on marketable securities, net of tax | -87,790 | |
| Other comprehensive income (loss) | Total other comprehensive income (loss) | $- | -87,790 |
| Other comprehensive income (loss) | Comprehensive loss | -9,140,038 | -7,621,061 |
| Loss per common share: | Basic and Diluted | -4.06 | -7.05 |
| Weighted average shares outstanding: | Basic and Diluted | 2,253,474 | 1,068,299 |
Balance Sheet
March 31, 2026 — (Unaudited)
| March 31, 2026 | December 31, 2025 | ||
|---|---|---|---|
| Current assets | Cash and cash equivalents | 8,230,984 | 11,884,607 |
| Current assets | Accounts receivable, net | 82,339 | 190,375 |
| Current assets | Inventory, net | 846,119 | 992,397 |
| Current assets | Income taxes receivable | 49 | 44,559 |
| Current assets | Prepaid expenses and other current assets | 622,760 | 581,527 |
| Current assets | Total current assets | 9,782,251 | 13,693,465 |
| Current assets | Property and equipment, net | 2,158,670 | 2,272,098 |
| Current assets | Operating lease right-of-use asset | 2,002,597 | 1,207,453 |
| Current assets | Intangible assets, net | 7,219,000 | 7,219,000 |
| Current assets | Investment in joint ventures | 337,208 | 350,569 |
| Current assets | Total assets | 21,499,726 | 24,742,585 |
| Current liabilities | Accounts payable | 2,017,852 | 1,878,225 |
| Current liabilities | Accrued expenses | 1,364,754 | 865,301 |
| Current liabilities | Operating lease liability, current | 857,638 | 662,258 |
| Current liabilities | Contingent consideration liabilities, current | 43,756 | 119,036 |
| Current liabilities | Deferred revenue | 600 | 14,800 |
| Current liabilities | Total current liabilities | 4,284,600 | 3,539,620 |
| Long-term liabilities | Operating lease liability | 1,172,716 | 574,301 |
| Long-term liabilities | Total long-term liabilities | 1,172,716 | 574,301 |
| Long-term liabilities | Total liabilities | 5,457,316 | 4,113,921 |
| Stockholders’ equity | Common stock, $0.001 par value; 100,000,000 shares authorized; 3,764,088 shares issued and 3,602,465 shares outstanding as of March 31, 2026 and 2,256,654 shares issued and 2,095,031 shares outstanding as of December 31, 2025 | 69,207 | 67,700 |
| Stockholders’ equity | Treasury stock, at cost; 161,623 shares held as of March 31, 2026 and December 31, 2025, respectively | -15,575,795 | -15,575,795 |
| Stockholders’ equity | Additional paid-in capital | 121,062,575 | 116,510,298 |
| Stockholders’ equity | Accumulated deficit | -89,513,577 | -80,373,539 |
| Stockholders’ equity | Total stockholders’ equity | 16,042,410 | 20,628,664 |
| Stockholders’ equity | Total liabilities and stockholders’ equity | 21,499,726 | 24,742,585 |
Full release
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,”
“expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include,... (truncated)ry submission, clearance, authorization, and commercialization of the Co-Dx PCR platform and related tests; (ii) anticipated timing and progress of clinical studies and regulatory submissions; (iii) commercialization and manufacturing activities involving CoSara and CoMira; (iv) anticipated market opportunities and international expansion initiatives; (v) the expected capabilities, differentiation, and adoption of the Company’s platform technologies; and (vi) the Company’s strategic, operational, and growth initiatives generally. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements.
There can be no assurance that any regulatory submission, authorization, commercialization milestone, manufacturing initiative, strategic collaboration, or market opportunity will occur on the timelines anticipated by the Company, or at all, due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange
Commission (SEC) on March 31, 2026, and in our other filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Company
Contact:
Andrew
Benson
Head of Investor Relations
+1
801-438-1036 investors@codiagnostics.com
Investor
Contact:
Valter
Pinto, Managing Director
KCSA
Strategic Communications
+1
212.896.1254
CODX@KCSA.com
Media
Contact:
Jennifer
Webb
ColtrinMethod
PR jcoltrin@coltrinmethodpr.com
CO-DIAGNOSTICS,
INC. AND SUBSIDIARIES